Immix Biopharma, Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Immix Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q3 2024.
Immix Biopharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 26.8 %, a 83.8% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	26.8	+12.2	+83.8%	Sep 30, 2024
Q2 2024	20.7	+9.29	+81.4%	Jun 30, 2024
Q1 2024	20.3	+12.2	+150%	Mar 31, 2024
Q4 2023	17	+11.5	+208%	Dec 31, 2023
Q3 2023	14.6	+11.6	+382%	Sep 30, 2023
Q2 2023	11.4			Jun 30, 2023
Q1 2023	8.1			Mar 31, 2023
Q4 2022	5.52			Dec 31, 2022
Q3 2022	3.02			Sep 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.